» Articles » PMID: 27748392

Minimal Change Disease and Idiopathic FSGS: Manifestations of the Same Disease

Overview
Journal Nat Rev Nephrol
Specialty Nephrology
Date 2016 Nov 8
PMID 27748392
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are the key histological findings in patients with idiopathic nephrotic syndrome (INS). Although MCD and idiopathic FSGS are often considered to represent separate entities based on differences in their presenting characteristics, histology and outcomes, little evidence exists for this separation. We propose that MCD and idiopathic FSGS are different manifestations of the same progressive disease. The gradual development of FSGS in patients with non-remitting or relapsing INS has been well documented. Moreover, FSGS is the uniform result of substantial podocyte loss in animal models, and a common feature of virtually all progressive human glomerulopathies. As evidence suggests a common aetiology, the pathogenesis of MCD and idiopathic FSGS should be studied together. In clinical trials, idiopathic FSGS should be considered to represent an advanced stage of disease progression that is less likely to respond to treatment than the earlier stage of disease, which is usually defined as MCD.

Citing Articles

Proteomic profiling of kidney biopsies in nephrotic syndrome.

Williams E, Fresquet M, Li A, Lawless C, Knight D, Colby E Wellcome Open Res. 2025; 9:731.

PMID: 39991116 PMC: 11845903. DOI: 10.12688/wellcomeopenres.22633.1.


Advancing the clinical assessment of glomerular podocyte pathology in kidney biopsies via super-resolution microscopy and angiopoietin-like 4 staining.

Liu X, Wang S, Liu G, Wang Y, Shang S, Zou G Theranostics. 2025; 15(3):784-803.

PMID: 39776814 PMC: 11700855. DOI: 10.7150/thno.101498.


MINIMAL CHANGE DISEASE IN PEOPLE LIVING WITH HIV: A CASE REPORT AND REVIEW OF THE LITERATURE.

Hidayani S, Syafrizal N, Jamaluddin P, Ong J Afr J Infect Dis. 2024; 19(1):79-83.

PMID: 39618540 PMC: 11607784. DOI: 10.21010/Ajidv19i1.9.


Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility.

Roman M, Nowicki M Int J Mol Sci. 2024; 25(22).

PMID: 39596249 PMC: 11595011. DOI: 10.3390/ijms252212174.


TRPC6 knockdown-mediated ERK1/2 inactivation alleviates podocyte injury in minimal change disease via upregulating Lon peptidase 1.

Ma J, Ren L, Su Q, Lv X, Sun M, Wei Y Ren Fail. 2024; 46(2):2431150.

PMID: 39566913 PMC: 11580150. DOI: 10.1080/0886022X.2024.2431150.


References
1.
Maas R, Deegens J, van den Brand J, Cornelissen E, Wetzels J . A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrol. 2013; 14:47. PMC: 3585752. DOI: 10.1186/1471-2369-14-47. View

2.
Gelberg H, Healy L, Whiteley H, Miller L, Vimr E . In vivo enzymatic removal of alpha 2-->6-linked sialic acid from the glomerular filtration barrier results in podocyte charge alteration and glomerular injury. Lab Invest. 1996; 74(5):907-20. View

3.
Tejani A . Morphological transition in minimal change nephrotic syndrome. Nephron. 1985; 39(3):157-9. DOI: 10.1159/000183363. View

4.
McCarthy E, Sharma M, Savin V . Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5(11):2115-21. DOI: 10.2215/CJN.03800609. View

5.
Meijers B, Maas R, Sprangers B, Claes K, Poesen R, Bammens B . The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014; 85(3):636-40. DOI: 10.1038/ki.2013.505. View